Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: cyberman who wrote (27839)	2/4/1999 12:45:00 PM
From: Henry Niman	Respond to of 32384

Maybe today's Reiterated BUY by Bear Stearns will help. The same language was incorporated into yesterday's Biotech Watch: "....we anticipate that Ligand will receive approval for its second product, ONTAK, within weeks of this approval. Following these two products are 3-4 additional products that the company should file with regulatory authorities within the next 12-18 months. We anticipate that by 2001, Ligand's specialty oncology sales force will be selling 4-6 products and generating sales in excess of $150 million...."

To: cyberman who wrote (27839)	2/4/1999 12:48:00 PM
From: Henry Niman	Respond to of 32384

Today's Bear Stearns regarding TIME: "We are hard pressed to find another biotechnology company with this type of late stage pipeline. The positive momentum behind Ligand is clearly building. We would encourage investors to begin establishing a position in Ligand's shares and ride the pending product wave."

To: cyberman who wrote (27839)	2/4/1999 12:56:00 PM
From: Henry Niman	Respond to of 32384

More on TIME: "Ligand announced yesterday that the company had received FDA approval for Panretin gel for the topical treatment of AIDS-related Kaposi's sarcoma. This is quite an accomplishment for a small biotechnology company considering that clinicals trials were initiated only 5 years ago. The company anticipates shipping product to its distributor within the next week. Ligand is still awaiting final approval of ONTAK for the treatment of cutaneous T cell lymphoma. We expect an approval and launch of this product in the current quarter. With two products soon to enter the market and 3-4 NDAs to be filed in the next 12-15 months, Ligand is poised to make the transition from a cash burning R&D company to a profitable specialty pharmaceutical company. Historically, it is during this period of transition that biotechnology companies experience significant share price appreciation. We believe that Ligand will not be an exception and therefore reiterate our Buy rating."